Investors ImmunoGen, Inc.
OVERVIEW
INVESTOR.IMMUNOGEN.COM TRAFFIC
Date Range
Date Range
Date Range
LINKS TO WEBSITE
WHAT DOES INVESTOR.IMMUNOGEN.COM LOOK LIKE?
INVESTOR.IMMUNOGEN.COM SERVER
WEBSITE ICON
SERVER SOFTWARE
We discovered that investor.immunogen.com is weilding the nginx operating system.SITE TITLE
Investors ImmunoGen, Inc.DESCRIPTION
The Investor Relations website contains information about ImmunoGen, Inc.s business for stockholders, potential investors, and financial analysts.PARSED CONTENT
The domain had the following on the site, "What is an ADC? What is an ADC? And in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda." I observed that the web site said " More information about the Company can be found at www." They also stated " ImmunoGen Presents Data from FORWARD II Assessment of Mirvetuximab Soravtansine in Combination with Pembrolizumab at the Society of Gynecologic Oncology Annual Meeting. May 9, 2018 at 920 AM EDT. There are no items to display."ANALYZE MORE WEB PAGES
InContact Reports Second Quarter 2015 Financial Results. InContact CEO Paul Jarman and CFO Greg Ayers to Present at the Oppenheimer 18th Annual Technology, Internet and Communications Conference. InContact Sets Second Quarter 2015 Conference Call. International Business Process Outsourcer Expands Existing inContact Solution with Workforce Management in the Cloud.
Q2 2015 Incyte Corporation Earnings Conference Call. Q2 2015 Incyte Corporation Earnings Conference Call. Click here to add this event to your calendar. Incyte to Report Second Quarter Financial Results on August 4.
Please contact your service provider for more details.
Укажите свой АКТУАЛЬНЫЙ емейл для гарантированного получения письма с персональной ссылкой. Мы гарантируем безопасность введенной Вами информации. И строить финансовую свободу шаг за шагом. Как не попасть в ловушки биржевой индустрии. Тестирование и анализ торговых стратегий. Практическое занятие по аукционам банкротств.
Every pharmaceutical company has the ability to develop medicines, but not all have the entrepreneurial spirit for truly innovative treatments. 10 Finderne Ave, Building 10. We are focused on developing and commercializing drugs that treat rare diseases.